Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT-Reference-Cited by-同舟云学术

Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT

Published:2024 Issue:1 Volume:64 Page:45-51
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:JCEH

Author:

Nakamura Takahisa¹,Tatetsu Hiro¹,Higuchi Yusuke¹,Endo Shinya¹,Shiraishi Shinya²,Kawanaka Koichi²,Imakane Daisuke¹,Sonoda Miyu¹,Furuta Rie¹,Shichijo Takafumi¹,Honda Yumi³,Karube Kennosuke⁴,Mikami Yoshiki³,Nosaka Kisato¹,Matsuoka Masao¹,Yasunaga Jun-ichirou¹

Affiliation:

1. Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,

2. Department of Diagnostic Radiology, Kumamoto University Hospital, Kumamoto, Japan,

3. Department of Pathology, Kumamoto University Hospital, Kumamoto, Japan,

4. Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Link

https://www.jstage.jst.go.jp/article/jslrt/64/1/64_23046/_pdf

Reference34 articles.

1. 1 Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.

2. 2 Suzuki R, Suzumiya J, Yamaguchi M et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010; 21: 1032-1040.

3. 3 Tse E, Zhao WL, Xiong J, Kwong YL. How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022; 15: 74.

4. 4 Kim SJ, Yoon DH, Jaccard A et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17: 389-400.

5. 5 Lim SH, Hong JY, Lim ST et al. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol. 2017; 28: 2199-2205.